Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease ...Middle East

Novel TL1A/IL23p19 bispecific antibody targets drivers of disease pathogenesis to overcome the efficacy ceiling in inflammatory bowel disease. License and collaboration agreement strengthen Boehringer's inflammatory disease pipeline with a potential, first-in-class, pre-clinical asset....

Hence then, the article about boehringer ingelheim and simcere partner to advance a dual target antibody treatment to address unmet needs in inflammatory bowel disease was published today ( Tuesday 27/01/2026 - 01:50 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Boehringer Ingelheim and Simcere partner to advance a dual-target antibody treatment to address unmet needs in inflammatory bowel disease )

Also on site :

• Mountain lion spotted in San Francisco's Pacific Heights neighborhood
• Aldi's 3-Piece Vintage-Inspired Apothecary Jar Set Will Elevate Your Bathroom Organization Beautifully
• Russia-Ukraine war: List of key events, day 1,433